Movatterモバイル変換

[0]ホーム

Jump to content

Eprotirome

Add links

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Eprotirome
Identifiers

IUPAC name 2-({3,5-Dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}carbamoyl)acetic acid
CAS Number	355129-15-6
PubChemCID	10299876
DrugBank	DB05035
ChemSpider	8475344
UNII	958AQ7B6R1
ChEMBL	ChEMBL2035874
CompTox Dashboard(EPA)	DTXSID00189021
Chemical and physical data
Formula	C₁₈H₁₇Br₂N₂O₅
Molar mass	501.151 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)C1=C(C=CC(=C1)OC2=C(C=C(C=C2Br)NC(=O)CC(=O)O)Br)O
InChI InChI=1S/C18H17Br2NO5/c1-9(2)12-7-11(3-4-15(12)22)26-18-13(19)5-10(6-14(18)20)21-16(23)8-17(24)25/h3-7,9,22H,8H2,1-2H3,(H,21,23)(H,24,25) Key:VPCSYAVXDAUHLT-UHFFFAOYSA-N

Eprotirome is athyromimetic drug that has been investigated for the treatment ofdyslipidemia. A Phase III trial in humans was discontinued after the drug was found to have negative effects oncartilage in dogs.^[1]^[2]

References

[edit]

^Saponaro, Federica; Sestito, Simona; Runfola, Massimiliano; Rapposelli, Simona; Chiellini, Grazia (2020)."Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders".Frontiers in Medicine.7: 331.doi:10.3389/fmed.2020.00331.ISSN 2296-858X.PMC 7363807.PMID 32733906.
^Unnikrishnan, A. G.; Baruah, Manash; Kalra, Sanjay (December 2012)."Thyromimetics: What does the future hold?".Indian Journal of Endocrinology and Metabolism.16 (Suppl 2):S159 –S161.doi:10.4103/2230-8210.104029.ISSN 2230-8210.PMC 3603016.PMID 23565368.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eprotirome&oldid=1207083773"

Categories:

Hidden categories:

[8]ページ先頭